Compass Therapeutics (CMPX) Current Assets (2018 - 2026)

Compass Therapeutics (CMPX) has 9 years of Current Assets data on file, last reported at $195.7 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 57.63% year-over-year to $195.7 million; the trailing twelve-month figure through Mar 2026 stood at $195.7 million (up 57.63% YoY), and the FY2025 full-year result was $209.8 million, up 58.05% from the prior year.
• Current Assets slipped to $195.7 million in Q1 2026, from $209.8 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $221.1 million in Q3 2025 to a low of $106.2 million in Q2 2025.
• A 5-year average of $159.7 million and a median of $153.9 million in 2023 frame the typical range for Current Assets.
• Across the five-year window, Current Assets soared 328.93% in 2022 and tumbled 30.84% in 2025, its largest moves.
• Tracing CMPX's Current Assets over 5 years: stood at $194.8 million in 2022, then dropped by 21.0% to $153.9 million in 2023, then retreated by 13.73% to $132.8 million in 2024, then soared by 58.05% to $209.8 million in 2025, then decreased by 6.74% to $195.7 million in 2026.
• Business Quant data shows CMPX's Current Assets at $195.7 million in Q1 2026, $209.8 million in Q4 2025, and $221.1 million in Q3 2025.